We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M Turnover 22.11%
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
+18%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$21.1M
Cap. Flow
-$3.54M
Cap. Flow %
-1.87%
Top 10 Hldgs %
62.82%
Holding
95
New
10
Increased
16
Reduced
4
Closed
11
Avg Time Held
2.3 years
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
CLST icon
Catalyst Bancorp
CLST
+$1.84M
2
SPRB icon
Spruce Biosciences
SPRB
+$1.12M
3
CGEM icon
Cullinan Oncology
CGEM
+$668K
4
INSM icon
Insmed
INSM
+$515K
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$512K

Top Sells

Rank Stock Value
1
CPRX icon
Catalyst Pharmaceutical
CPRX
+$2.97M
2
ACLX icon
Arcellx
ACLX
+$2.23M
3
CYTK icon
Cytokinetics
CYTK
+$1.56M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$1.55M
5
TGTX icon
TG Therapeutics
TGTX
+$948K

Sector Composition

Rank Sector Weight
1 Healthcare 52.57%
2 Financials 20.08%
3 Communication Services 17.13%
4 Miscellaneous 7.75%
5 Technology 1.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARDX icon
26
Ardelyx
ARDX
$824M
$1.34M 0.71%
263,168
+56,168
+27% +$343K
2026 Q1
1 quarter
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$1.47B
$1.27M 0.67%
38,069
+5,000
+15% +$124K
2025 Q1
5 quarters
CLOZ icon
28
Panagram BBB-B CLO ETF
CLOZ
$785M
$1.26M 0.67%
47,807
– –
2023 Q3
11 quarters
CGEM icon
29
Cullinan Oncology
CGEM
$878M
$1.26M 0.67%
69,182
+44,982
+186% +$668K
2026 Q1
1 quarter
JNJ icon
30
Johnson & Johnson
JNJ
$612B
$1.25M 0.66%
4,922
– –
2021 Q4
18 quarters
VERA icon
31
Vera Therapeutics
VERA
$1.93B
$1.12M 0.59%
26,000
– –
2025 Q1
5 quarters
OBIO icon
32
Orchestra BioMed
OBIO
$339M
$1.09M 0.58%
253,651
– –
2025 Q2
4 quarters
SPRB icon
33
Spruce Biosciences
SPRB
$112M
$1.08M 0.57%
+20,000
New +$1.12M
2026 Q2
0 quarters
CNTB icon
34
Connect Biopharma Holdings
CNTB
$57.2M
$1.06M 0.56%
444,862
+57,027
+15% +$138K
2025 Q4
2 quarters
IBB icon
35
iShares Biotechnology ETF
IBB
$10.4B
$1.05M 0.55%
5,500
– –
2025 Q2
4 quarters
BIIB icon
36
Biogen
BIIB
$34.4B
$864K 0.46%
4,000
– –
2025 Q3
3 quarters
PFE icon
37
Pfizer
PFE
$166B
$779K 0.41%
32,337
– –
2021 Q4
18 quarters
AAPL icon
38
Apple
AAPL
$5.01T
$722K 0.38%
2,494
– –
2021 Q4
18 quarters
CNQ icon
39
Canadian Natural Resources
CNQ
$107B
$664K 0.35%
16,800
– –
2021 Q4
18 quarters
PTHS icon
40
Pelthos Therapeutics
PTHS
$77.5M
$624K 0.33%
22,073
+1,000
+5% +$25.7K
2025 Q3
3 quarters
IBM icon
41
IBM
IBM
$215B
$602K 0.32%
2,142
– –
2023 Q1
13 quarters
MSFT icon
42
Microsoft
MSFT
$3.96T
$597K 0.32%
1,600
– –
2021 Q4
18 quarters
VSTM icon
43
Verastem
VSTM
$698M
$592K 0.31%
155,000
+51,000
+49% +$247K
2026 Q1
1 quarter
KURA icon
44
Kura Oncology
KURA
$855M
$579K 0.31%
52,767
– –
2025 Q3
3 quarters
SLDB icon
45
Solid Biosciences
SLDB
$585M
$562K 0.3%
56,208
+9,065
+19% +$68.7K
2025 Q1
5 quarters
INSM icon
46
Insmed
INSM
$21.4B
$453K 0.24%
+4,253
New +$515K
2026 Q2
0 quarters
LBRX icon
47
LB Pharmaceuticals
LBRX
$1.1B
$421K 0.22%
+12,965
New +$381K
2026 Q2
0 quarters
CDNA icon
48
CareDx
CDNA
$3.35B
$388K 0.21%
+13,630
New +$297K
2026 Q2
0 quarters
QTTB icon
49
Q32 Bio
QTTB
$238M
$387K 0.2%
+30,412
New +$254K
2026 Q2
0 quarters
ELVN icon
50
Enliven Therapeutics
ELVN
$2.88B
$314K 0.17%
+6,183
New +$262K
2026 Q2
0 quarters
1
2
3 4

Similar funds

SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM
SHC
SALT Holding Corp Wilmington, Delaware $189M AUM 34.63% 1-Year Est. Return
HC
Hara Capital Bellevue, Washington $190M AUM 42.56% 1-Year Est. Return

David M. Knott Jr's Q2 2026 Portfolio in Review

As of Q2 2026, David M. Knott Jr held 95 positions worth $189M, up 13% from $168M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

David M. Knott Jr's Q2 2026 filing shows 10 new, 16 increased, 4 reduced and 11 closed positions. Its largest new stake was Catalyst Bancorp: 114,000 shares worth $3.58M. The largest sale was Catalyst Pharmaceutical, an estimated $2.97M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 54% a quarter earlier, followed by Financials and Communication Services.

  • David M. Knott Jr's largest Q2 2026 buy was Catalyst Bancorp: 114,000 shares worth $3.58M.
  • David M. Knott Jr added most to Cullinan Oncology in Q2 2026, an estimated $668K increase.
  • David M. Knott Jr's biggest Q2 2026 reduction was TG Therapeutics, cutting an estimated $948K.
  • David M. Knott Jr fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $2.97M.
  • David M. Knott Jr's ten largest holdings make up 63% of its $189M portfolio in Q2 2026.
  • David M. Knott Jr opened 10 new positions and closed 11 in Q2 2026.
  • David M. Knott Jr's portfolio value rose 13% quarter-over-quarter to $189M.

Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.